Editas Medicine (EDIT) Posts Smaller Q3 Loss

Editas Medicine (NASDAQ: EDIT) reported Q3 EPS of ($0.32), $0.34 better than the analyst estimate of ($0.66). Revenue for the quarter came in at $14.52 million versus the consensus estimate of $9.83 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Medtronic completes $550 million Scientia Vascular acquisition
• RH (RH) Tops Q1 EPS by 12c